Nom du produit:5,7-dichloro-3-isopropylpyrazolo[1,5-a]pyrimidine
IUPAC Name:5,7-dichloro-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidine
- CAS:771510-32-8
- Formule moléculaire:C9H9Cl2N3
- Pureté:95%+
- Numéro de catalogue:CM151764
- Poids moléculaire:230.09
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:771510-32-8
- Formule moléculaire:C9H9Cl2N3
- Point de fusion:-
- Code SMILES:CC(C)C1=C2N=C(Cl)C=C(Cl)N2N=C1
- Densité:
- Numéro de catalogue:CM151764
- Poids moléculaire:230.09
- Point d'ébullition:
- N° Mdl:MFCD12923044
- Stockage:Store at 2-8°C.
Category Infos
- Pyrazolopyrimidines
- Pyrazolopyrimidine scaffolds are one of the most important heterocyclic compounds in drug discovery. This scaffold has various biological activities, among which anticancer is an important one.
Column Infos
- Samuraciclib
- Carrick Therapeutics’ Phase 2 Clinical Trial of Samuraciclib combined with Fulvestrant has dosed its first patient. The study targets patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Samuraciclib is a selective oral, first-in-class inhibitor of CDK7. It is involved in the regulation of cancer-causing genes, promotion of uncontrolled cell cycle progression, and increase in resistance to anti-hormone therapy. The comb previously receives the Fast Track Designation from the U.S. FDA.